<DOC>
	<DOCNO>NCT00638131</DOCNO>
	<brief_summary>There little doubt necessity improvement prevention therapy end-stage renal disease . Despite success ARB treat diabetic nephropathy , patient obtain satisfactory control blood pressure , albuminuria decline renal function . Experimental data provide u rationale potential add benefit ET receptor blockade AII inhibition diabetic renal protection . Considering nephroprotective effect bosentan diabetic rat , clinical study warrant ass whether ET receptor antagonism additive renoprotective effect top AII inhibition .</brief_summary>
	<brief_title>Bosentan Use Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Men woman ≥ 18 year age body weight ≥ 40 kg ; For female patient , nonpregnant woman surgically sterile , postmenopausal document infertility ( 50 year age amenorrheic least 1 year ) , childbearing potential use intrauterine device ( IUDs ) ; Patients diagnose Type 2 diabetes overt nephropathy ( urinary albumin excretion ≥ 300mg/24h ) ; Patients current treatment angiotensin II receptor blocker ≥ 3 month ; Patients stable least 3 month prior screen ( change medication diabetic nephropathy ) ; Provide write informed consent ; Patients history pulmonary chronic obstructive disease , cardiac failure coronary artery disease ; Patients document cancer , acute infection chronic inflammatory disease ; Patients pregnant breastfeeding ; Patients know hepatic disorder AST ∕or ALT upper normal limit ; Patients hemoglobin hematocrit ≥ 30 % normal range ( patient secondary polycythemia permit ) ; Patients systolic blood pressure &lt; 110mm Hg ; Patients plasmatic albumin level &lt; 30g/L ; Patients document creatinine clearance ≤ 60ml/min ; Patients anticoagulant antiinflammatory drug , include cyclooxygenase inhibitor , AINS , prednisone immunosuppressive drug , platelet aggregation inhibitor , except low dose aspirin , ACE inhibitor , antidiabetic agent ( rosiglitazone , pioglitazone ) antioxidant ( vitamin E ) ( except statin lowdose aspirin ≤ 80mg/day ) ; Patients treatment plan treatment another investigational drug ; Patients receive endothelin receptor antagonist , phosphodiesterase type 5 inhibitor , prostanoid ( exclude acute administration catheterization procedure test vascular reactivity ) within 2 month inclusion ; Patients receive calcineurininhibitors ( i.e. , cyclosporine A tacrolimus ) , fluconazole , glibenclamide ( glyburide ) inclusion expect receive drug study ; Patients know hypersensitivity bosentan excipients ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>